TP53 and neoplasm: Simple modifications to MHC anchor residues, which substitute for suboptimal anchor residues, have proven effective in enhancing the immunogenicity of tumor-associated antigens, including gp100, p53, Trp-1, and survivin [135, 136, 139–141].